Tempest Reports 100% CR Rate in Ongoing REDEEM-1 Trial of TPST-2003.
ByAinvest
Wednesday, Feb 25, 2026 8:15 am ET1min read
TPST--
Tempest Therapeutics has announced interim results from its REDEEM-1 trial of TPST-2003, a treatment for relapsed/refractory multiple myeloma. The trial achieved a 100% complete response rate among all six efficacy evaluable patients, with a favorable safety profile and no Grade >3 CRS or ICANS. The prior investigator-initiated trial reached a median progression-free survival of 23.1 months, including in patients with extramedullary disease. Tempest plans to submit a U.S. IND and initiate a U.S. registrational study in 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet